RosenheckRAKrystalJHLewR. Challenges in the design and conduct of clinical effectiveness trials in schizophrenia. Clin Trials2011; 8: 196–204.
2.
SchulzCTimmJCordesJ. Patient-oriented randomisation: A new trial design applied in the Neuroleptic Strategy Study. Clin Trials2016; 13: 251–259.
3.
KahnRSFleischhackerWWBoterH.; EUFEST Study Group. Effectiveness of antipsychotic drugs in first-episode schizophrenia and schizophreniform disorder: an open label randomised clinical trial. Lancet2008; 371: 1085–1097.
4.
LiebermanJAStroupTSMcEvoyJP.; Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) Investigators. Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. N Eng J Med2005; 353: 1209–1223.
5.
JonesPBBarnesTRDaviesL. Randomised controlled trial of the effect on quality of life of second- vs first-generation antipsychotic drugs in schizophrenia: Cost Utility of the Latest Antipsychotic Drugs in Schizophrenia Study (CUtLASS 1). Arch Gen Psychiatry2006; 63: 1079–87.
6.
LewisSWBarnesTRDaviesL. Randomised controlled trial of effect of prescription of clozapine versus other second-generation antipsychotic drugs in resistant schizophrenia. Schizophr Bull2006; 32: 715–723.
